Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.51 |
| ▸ | BRD1 | O95696 | 1/20 | 0.51 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956219 | 0.93 | KEAP1 (0.63) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL7571563 | 0.92 | STAT3 (0.61) | STAT3FFAR4KEAP1NFE2L2SQSTM1 | |
| SCHEMBL5955235 | 0.89 | CYP2C9 (0.59) | FFAR4FFAR1 | |
| SCHEMBL5955308 | 0.88 | PGR (0.70) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL5955223 | 0.88 | FFAR4 (0.68) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL5955419 | 0.86 | LMNA (0.64) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL5955460 | 0.86 | PGR (0.65) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL5955279 | 0.84 | KEAP1 (0.53) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL5955241 | 0.84 | KEAP1 (0.53) | FFAR4KEAP1NFE2L2SQSTM1PGR | |
| SCHEMBL5955289 | 0.84 | KEAP1 (0.53) | FFAR4KEAP1NFE2L2SQSTM1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006014405-A2 | SULFONAMIDE-BASED COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-09 | — | — | WO | claimed |
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | claimed |
| WO-2006014405-A2 | SULFONAMIDE-BASED COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | SRC, LCK, ABL1 | STAT3 355/4885FFAR4 3859/4885KEAP1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.